Baxter International (BAX) Stock Analysis & Winston Score

Baxter International makes medical products that hospitals and clinics use every day to keep patients alive and healthy. Its core products include IV fluids, dialysis machines, and equipment used in surgery and intensive care units. Baxter is one of the largest suppliers of intravenous solutions in the United States, making it a critical part of hospital supply chains. Baxter sells its products directly to hospitals, dialysis centers, and healthcare systems across more than 100 countries, generating revenue through product sales rather than subscriptions or software licenses. The company's scale and long-standing relationships with hospital networks give it some competitive stability, but its negative operating and return-on-invested-capital margins signal that costs are currently outpacing revenue. Baxter is working through a significant debt load following its 2022 acquisition of Hillrom, and its ability to cut costs, improve margins, and potentially spin off its kidney care division are the key factors that will shape its financial recovery.